2023 World Conference on Lung Cancer (Posters)-P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib

P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to examine the treatment patterns and clinical outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) after progression on first-line osimertinib, a third-generation EGFR tyrosine kinase inhibitor. The researchers conducted a retrospective analysis using a large database of over 80,000 patients with advanced NSCLC. Among the 2,347 patients treated with first-line osimertinib, 541 had a documented second-line treatment initiated between 2016 and 2022. The most common EGFR mutations were exon 19 deletion and exon 21 L858R. Second-line treatment regimens varied, with 65% including chemotherapy, 37% including an immune checkpoint inhibitor, and 44% including an EGFR TKI (of which 62% was osimertinib). <br /><br />The study found that the inclusion of an EGFR TKI with chemotherapy was associated with superior progression-free survival (median: 11.0 versus 5.7 months) and overall survival (median: 12.0 versus 17.6 months) compared to other chemotherapy approaches without a TKI. These findings suggest that continuing an EGFR TKI with chemotherapy may enhance outcomes in patients with good performance status. <br /><br />The study highlights the highly variable approach to second-line therapy following progression on osimertinib and calls for further study to evaluate the comparative effectiveness of second-line therapy in this context. The results provide valuable real-world perspective on the management of EGFR-mutant NSCLC after progression on first-line osimertinib and emphasize the importance of individualized treatment strategies.

Asset Subtitle

Sarah Goldberg

Meta Tag

Speaker Sarah Goldberg

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

EGFR-mutant non-small cell lung cancer

treatment patterns

clinical outcomes

osimertinib

retrospective analysis

second-line treatment

EGFR mutations

chemotherapy

progression-free survival

individualized treatment strategies